Utilization of Evidence Blueprint Initiative to Transform Capability Development in AstraZeneca Spain.

The role of Medical Affairs (MA) has shifted from traditional evidence dissemination to an integrated process leveraging real-world data (RWD) and diverse data sources. To adapt and lead this shift, AstraZeneca (AZ) Spain recognized the essential need to identify gaps in evidence-generation capabilities and establish targeted strategies aligned with both global and local priorities. The objective of this work was to assess AZ Spain's current evidence-generation capabilities and identify areas for improvement by using the so-called "Evidence Blueprint" framework. To do this, we conducted a systematic self-assessment following the Blueprint to evaluate performance across ten core areas. An approach to identify gaps and enhance evidence-generation processes was undertaken in four phases: defining capabilities, assessing maturity, developing a roadmap for improvement, and implementing changes. The self-assessment identified five priority areas, including two focused priorities-Innovative Value Strategies/Payer Evidence and RWD Vision and Strategy-as well as three improvement areas-Evidence Planning and Value Team Implementation, Research/Evidence Partnerships, and Patient-Centric Evidence. Tangible actions included the development of processes to assess outcome-based agreements, comprehensive mapping of existing national and regional databases to strengthen RWD strategies, creating a cross-functional strategy for evidence planning, establishing research partnerships leveraging European funding, and adopting patient-centric methodologies such as ethnographic studies and patient-authored publications. The initiatives undertaken by AZ Spain demonstrate the transformative potential of an Evidence Blueprint framework in addressing gaps and enhancing evidence-generation capabilities. By aligning local strategies with AZ's MA 2030 vision, these efforts ensure continuous innovation, improvement of decision-making, and a more substantial contribution to the healthcare ecosystem.